Effect of statins on toll-like receptors: a new insight to pleiotropic effects

被引:149
作者
Bahrami, Afsane [1 ]
Parsamanesh, Negin [2 ]
Atkin, Stephen L. [3 ]
Banach, Maciej [4 ,5 ]
Sahebkar, Amirhossein [6 ,7 ,8 ]
机构
[1] Birjand Univ Med Sci, Cellular & Mol Res Ctr, Birjand, Iran
[2] Birjand Univ Med Sci, Student Res Comm, Birjand, Iran
[3] Weill Cornell Med Qatar, Doha, Qatar
[4] Med Univ Lodz, WAM Univ Hosp Lodz, Dept Hypertens, Zeromskiego 113, Lodz, Poland
[5] PMMHRI, Lodz, Poland
[6] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, Iran
[7] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Iran
[8] Mashhad Univ Med Sci, Sch Pharm, Mashhad, Iran
关键词
HMG-CoA reductase; TLR; Inflammation; Atherosclerosis; Statins; KAPPA-B ACTIVATION; VASCULAR SMOOTH-MUSCLE; CORONARY-HEART-DISEASE; RHEUMATOID-ARTHRITIS; TOLL-LIKE-RECEPTOR-4; EXPRESSION; SIGNALING PATHWAY; ATHEROSCLEROTIC PLAQUES; INFLAMMATORY MEDIATORS; CYTOKINE PRODUCTION; ENDOGENOUS LIGANDS;
D O I
10.1016/j.phrs.2018.08.014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The toll-like receptors (TLRs) are a class of transmembrane-spanning receptors that are sentinels of both innate and adaptive immunity. Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are the most commonly prescribed therapeutic agents for treating hypercholesterolemia globally. However, statin therapy appears to have pleiotropic effects including attenuation of chronic low-grade inflammation and modulation of TLR activity. Statins through abolition of TLR4 expression and regulation of the TLR4/Myd88/NF-kappa B signaling pathway may slow the progression of atherosclerosis and other inflammatory diseases. In this review, we have focused on the impact and mechanism of action of statins on cardiovascular and non-cardiovascular diseases.
引用
收藏
页码:230 / 238
页数:9
相关论文
共 136 条
[1]   Innate immunity and toll-like receptors: Clinical implications of basic science research [J].
Abreu, MT ;
Arditi, M .
JOURNAL OF PEDIATRICS, 2004, 144 (04) :421-429
[2]   Toll-like receptors in the induction of the innate immune response [J].
Aderem, A ;
Ulevitch, RJ .
NATURE, 2000, 406 (6797) :782-787
[3]   Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation [J].
Ajamieh, Hussam ;
Farrell, Geoffrey ;
Wong, Heng Jian ;
Yu, Jun ;
Chu, Eagle ;
Chen, Jeffrey ;
Teoh, Narci .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (08) :1353-1361
[4]   Pathogen recognition and innate immunity [J].
Akira, S ;
Uematsu, S ;
Takeuchi, O .
CELL, 2006, 124 (04) :783-801
[5]   Toll-like receptor signalling [J].
Akira, S ;
Takeda, K .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (07) :499-511
[6]   Atorvastatin protected from paraquat-induced cytotoxicity in alveolar macrophages via down-regulation of TLR-4 [J].
Alizadeh-Tabrizi, Nazli ;
Malekinejad, Hassan ;
Varasteh, Soheil ;
Cheraghi, Hadi .
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2017, 49 :8-13
[7]   Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? [J].
Andreakos, E ;
Foxwell, B ;
Feldmann, M .
IMMUNOLOGICAL REVIEWS, 2004, 202 :250-265
[8]   Inflammatory mediators in chronic heart failure: An overview [J].
Anker, SD ;
von Haehling, S .
HEART, 2004, 90 (04) :464-470
[9]  
[Anonymous], AM J PHYSL HEART CIR
[10]  
[Anonymous], TRENDS CARDIOVASC ME